Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01590459 · ClinicalTrials.gov registry record · Phase 2
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT01590459 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 359 participants.
The verdict
NCT01590459, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor, for treatment of subjects with active RA who have had an inadequate response to Methotrexate.
Interventions
- DRUG VX-509
- DRUG VX-509 matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01590459
The ClinicalTrials.gov registry entry for NCT01590459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 359 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VX-509 is the first listed.
NCT01590459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01590459 about?
NCT01590459 is a clinical study titled "24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate". This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor, for treatment of subjects with active RA who have had an inadequate response to Methotrexate.
What is the current status of trial NCT01590459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2012-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01590459?
The interventions under investigation include: VX-509 (DRUG), VX-509 matching placebo (DRUG).
Who is sponsoring clinical trial NCT01590459?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.